Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Mayo Clinic
European Organisation for Research and Treatment of Cancer - EORTC
Sun Yat-sen University
Hoffmann-La Roche
Jonsson Comprehensive Cancer Center
Tokyo Medical and Dental University
Sun Yat-sen University
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Vaccinogen Inc
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
University Hospital, Lille
Philogen S.p.A.
Norwegian Department of Health and Social Affairs
SWOG Cancer Research Network
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
The Hospital of Vestfold
AstraZeneca
Fudan University
Centre Hospitalier Universitaire Dijon
All India Institute of Medical Sciences, Jodhpur
Alliance for Clinical Trials in Oncology
Sichuan Cancer Hospital and Research Institute
Bristol-Myers Squibb
Krankenhaus Nordwest
Philogen S.p.A.
Nova Scotia Health Authority
University Hospital, Bordeaux
Hoffmann-La Roche
Qilu Pharmaceutical Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University
Fondazione Michelangelo
Fondazione Michelangelo
Jagiellonian University
Swiss Cancer Institute
Sun Yat-sen University
University of Aleppo
Hoffmann-La Roche
Shanghai Pulmonary Hospital, Shanghai, China
Alliance for Clinical Trials in Oncology
Nantes University Hospital
CEL-SCI Corporation
Spanish Lung Cancer Group
Umeå University